UBE2S

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, UBE2S Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated UBE2S data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher UBE2S Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2S expression acts as an unfavorable survival marker.

THYM and BLCA are the cancer types where UBE2S Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
THYMOSMedianIII,IV0.1030.944<.00142view →
BLCAOSMedianIII,IV0.2080.686<.00136view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

UBE2S–THYM (OS)

Kaplan–Meier survival curve for UBE2S mutant vs wild-type samples in THYM.

Open the THYM breakdown →

Exploration